Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS
Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for ...
Donanemab patient: ‘The drug kept me feeling normal, but i’m scared about what happens next’
A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal ...
Outsourcing-pharma4h
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
STAT11h
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...
Eli Lilly announces MHRA grants marketing authorization for donanemab
Eli Lilly (LLY) announced that the Medicines and Healthcare products Regulatory Agency, or MHRA, has granted marketing authorization for ...
Armed robbery in Revesby11h
Donanemab Approved for Early Alzheimer's in Adults
Donanemab works by removing a sticky protein called beta-amyloid from the brain that is believed to cause Alzheimer's disease, and in the trials ...
National Institute for Health and Care Excellence11h
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...